Engineering T cell response to cancer antigens by choice of focal therapeutic conditions

References

• Diederich CJ. Thermal ablation and high-temperature thermal therapy: overview of technology and clinical implementation. Int J Hyperther. 2005;21:745–753.
   PubMed Web of Science ®Google Scholar
• Bai JF, Liu P, Xu LX. Recent advances in thermal treatment techniques and thermally induced immune responses against cancer. Ieee Trans Biomed Eng. 2014;61:1497–1505.
   PubMed Web of Science ®Google Scholar
• Scheffer HJ, Nielsen K, de Jong MC, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 2014;25:997–1011.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Brace CL, Lee FT, et al. Principles of and advances in percutaneous ablation. Radiology. 2011;258:351–369.
   PubMed Web of Science ®Google Scholar
• Paulet E, Aube C, Pessaux P, et al. Factors limiting complete tumor ablation by radiofrequency ablation. Cardiovasc Intervent Radiol. 2008;31:107–115.
   PubMed Web of Science ®Google Scholar
• Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14:199–208.
   PubMed Web of Science ®Google Scholar
• den Brok MH, Nierkens S, Wagenaars JA, et al. Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction. Vaccine. 2012;30:737–744.
   PubMed Web of Science ®Google Scholar
• Bhowmick P, Coad JE, Bhowmick S, et al. In vitro assessment of the efficacy of thermal therapy in human benign prostatic hyperplasia. Int J Hyperther. 2004;20:421–439.
   PubMed Web of Science ®Google Scholar
• Baust JG, Gage AA. The molecular basis of cryosurgery. Bju Int. 2005;95:1187–1191.
   PubMed Web of Science ®Google Scholar
• Jiang CL, Davalos RV, Bischof JC. A review of basic to clinical studies of irreversible electroporation therapy. Ieee Trans Biomed Eng. 2015;62:4–20.
   PubMed Web of Science ®Google Scholar
• Liu F, Roy P, Shao Q, et al. The role of protein loss and denaturation in determining outcomes of heating, cryotherapy, and irreversible electroporation on Cardiomyocytes. J Biomech Eng-T Asme. 2018;140. doi:10.1115/1.4039375.
   Web of Science ®Google Scholar
• Shao Q, Liu F, Chung C, et al. Physical and chemical enhancement of and adaptive resistance to irreversible electroporation of pancreatic cancer. Ann Biomed Eng. 2018;46:25–36.
   PubMed Web of Science ®Google Scholar
• Shao Q, Burbach B, Ramadhyan S, et al. Cryosurgery with vascular and immune adjuvants to address local and systemic cancer. Cryobiology. 2016;73:414.
   Google Scholar
• Lugnani F, Macchioro M, Rubinsky B. Cryoelectrolysis-electrolytic processes in a frozen physiological saline medium. Peerj. 2017;5:e2810.
   PubMed Web of Science ®Google Scholar
• Zhu J, Zhang Y, Zhang AL, et al. Cryo-thermal therapy elicits potent anti-tumor immunity by inducing extracellular Hsp70-dependent MDSC differentiation. Sci Rep. 2016;6:27136.
   PubMed Web of Science ®Google Scholar
• Redondo P, del Olmo J, de Cerio ALD, et al. Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. J Invest Dermatol. 2007;127:1673–1680.
   PubMed Web of Science ®Google Scholar
• Lindner U, Trachtenberg J, Lawrentschuk N. Focal therapy in prostate cancer: modalities, findings and future considerations. Nat Rev Urol. 2010;7:562–571.
   PubMed Web of Science ®Google Scholar
• Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. Am J Roentgenol. 2000;174:323–331.
   PubMed Web of Science ®Google Scholar
• Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378:607–620.
   PubMed Web of Science ®Google Scholar
• Zhang HG, Mehta K, Cohen P, et al. Hyperthermia on immune regulation: a temperature's story. Cancer Lett. 2008;271:191–204.
   PubMed Web of Science ®Google Scholar
• Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Invest Drugs. 2009;10:550–558.
   PubMed Web of Science ®Google Scholar
• Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology. 2009;58:1–11.
   PubMed Web of Science ®Google Scholar
• Sabel MS, Su G, Griffith KA, et al. Rate of freeze alters the immunologic response after cryoablation of breast cancer. Ann Surg Oncol. 2010;17:1187–1193.
   PubMed Web of Science ®Google Scholar
• Shenoi MM, Iltis I, Choi J, et al. Nanoparticle delivered vascular disrupting agents (vdas): use of tnf-alpha conjugated gold nanoparticles for multimodal cancer therapy. Mol Pharmaceutics. 2013;10:1683–1694.
   PubMed Web of Science ®Google Scholar
• Johnson EE, Yamane BH, Buhtoiarov IN, et al. Radiofrequency ablation combined with ks-il2 immunocytokine (emd 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res. 2009;15:4875–4884.
   PubMed Web of Science ®Google Scholar
• Chen ZB, Shen SQ, Peng BG, et al. Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model. Int J Hyperther. 2009;25:374–382.
   PubMed Web of Science ®Google Scholar
• den Brok M, Sutmuller RPM, Nierkens S, et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res. 2006;66:7285–7292.
   PubMed Web of Science ®Google Scholar
• Hamamoto S, Okuma T, Yamamoto A, et al. Radiofrequency ablation and immunostimulant ok-432: combination therapy enhances systemic antitumor immunity for treatment of vx2 lung tumors in rabbits. Radiology. 2013;267:405–413.
   PubMed Web of Science ®Google Scholar
• Machlenkin A, Goldberger O, Tirosh B, et al. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Clin Cancer Res. 2005;11:4955–4961.
   PubMed Web of Science ®Google Scholar
• den Brok M, Sutmuller RPM, Nierkens S, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer. 2006;95:896–905.
   PubMed Web of Science ®Google Scholar
• Waitz R, Solomon SB, Petre EN, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012;72:430–439.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery. 2018 [cited 2018 May 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT03325101
   Google Scholar
• ClinicalTrials.gov [Internet]. Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer (CryoIT). 2018 [cited 2018 May 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT02423928
   Google Scholar
• ClinicalTrials.gov [Internet]. A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer. 2018 [cited 2018 May 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT02833233
   Google Scholar
• ClinicalTrials.gov. A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC). Available from: https://clinicaltrials.gov/ct2/show/NCT02821754
   Google Scholar
• Gajewski TF, Woo SR, Zha YY, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol. 2013;25:268–276.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–489.
   PubMed Web of Science ®Google Scholar
• Silvestrini MT, Ingham ES, Mahakian LM, et al. Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols. Jci Insight. 2017;2:e90521.
   PubMed Web of Science ®Google Scholar
• Mescher MF, Popescu FE, Gerner M, et al. Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors. Semin Cancer Biol. 2007;17:299–308.
   PubMed Web of Science ®Google Scholar
• van den Bijgaart RJE, Eikelenboom DC, Hoogenboom M, et al. Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies. Cancer Immunol Immunother. 2017;66:247–258.
   PubMed Web of Science ®Google Scholar
• Kobayashi KS, van den Elsen PJ. NLRC5: a key regulator of MHC class I-dependent immune responses. Nat Rev Immunol. 2012;12:813–820.
   PubMed Web of Science ®Google Scholar
• Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107:4275–4280.
   PubMed Web of Science ®Google Scholar
• Ya Z, Hailemichael Y, Overwijk W, et al. Mouse model for pre-clinical study of human cancer immunotherapy. Current protocols in immunology. Hoboken (NJ): John Wiley & Sons, Inc.; 2001.
   Google Scholar
• Ngiow SF, Loi S, Thomas D, et al. Mouse models of tumor immunotherapy. Tumor Immunol. 2016;130:1–24.
   Web of Science ®Google Scholar
• Miller LM, Bourassa MW, Smith RJ. FTIR spectroscopic imaging of protein aggregation in living cells. Biochimica Et Biophysica Acta-Biomembranes. 2013;1828:2339–2346.
   Web of Science ®Google Scholar
• Yang HY, Yang SN, Kong JL, et al. Obtaining information about protein secondary structures in aqueous solution using Fourier transform IR spectroscopy. Nat Protocols. 2015;10:382–396.
   PubMed Web of Science ®Google Scholar
• Barth A. Infrared spectroscopy of proteins. Biochimica Et Biophysica Acta-Bioenergetics. 2007;1767:1073–1101.
   PubMed Web of Science ®Google Scholar
• He XM, Wolkers WF, Crowe JH, et al. In situ thermal denaturation of proteins in dunning AT-1 prostate cancer cells: implication for hyperthermic cell injury. Ann Biomed Eng. 2004;32:1384–1398.
   PubMed Web of Science ®Google Scholar
• Watkins SK, Zhu ZQ, Watkins KE, et al. Isolation of immune cells from primary tumors (Retracted article. See 2016). J Vis Exp. 2012;64:e3952.
   Google Scholar
• Zhu ZQ, Cuss SM, Singh V, et al. CD4(+) T cell help selectively enhances high-avidity tumor antigen-specific CD8(+) T cells. JI. 2015;195:3482–3489.
   Google Scholar
• Xu YK, Zhan YF, Lew AM, et al. Differential development of murine dendritic cells by GM-CSF versus flt3 ligand has implications for inflammation and trafficking. J Immunol. 2007;179:7577–7584.
   PubMed Web of Science ®Google Scholar
• Mitchell JS, Burbach BJ, Srivastava R, et al. Multistage T cell-dendritic cell interactions control optimal CD4 T cell activation through the ADAP-SKAP55-signaling module. J Immunol. 2013;191:2372–2383.
   PubMed Web of Science ®Google Scholar
• Fiege JK, Beura LK, Burbach BJ, et al. Adhesion- and degranulation-promoting adapter protein promotes CD8 T cell differentiation and resident memory formation and function during an acute infection. JI. 2016;197:2079–2089.
   Google Scholar
• Seong SY, Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol. 2004;4:469–478.
   PubMed Web of Science ®Google Scholar
• Dick LR, Aldrich C, Jameson SC, et al. Proteolytic processing of ovalbumin and beta-galactosidase by the proteasome to yield antigenic peptides. J Immunol. 1994;152:3884–3894.
   PubMed Web of Science ®Google Scholar
• Michalek MT, Grant EP, Rock KL. Chemical denaturation and modification of ovalbumin alters its dependence on ubiquitin conjugation for class I antigen presentation. J Immunol. 1996;157:617–624.
   PubMed Web of Science ®Google Scholar
• Bastianpillai C, Petrides N, Shah T, et al. Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment. Tumor Biol. 2015;36:9137–9146.
   PubMed Web of Science ®Google Scholar
• Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:E498–E509.
   PubMed Web of Science ®Google Scholar
• Takaki H, Cornelis FH. Can the combination of ablation and immunomodulation become the breakthrough of cancer treatment?. Diagn Interv Imaging. 2018;99:121–122.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH. The immune revolution: a case for priming, not checkpoint. Cancer Cell. 2018;33:563–569.
   PubMed Web of Science ®Google Scholar
• Stam AGM, de Gruijl TD. From local to systemic treatment: leveraging antitumor immunity following irreversible electroporation. In: Meijerink MR, Scheffer HJ, Narayanan G, editors. Irreversible electroporation in clinical practice. Cham: Springer International Publishing; 2018. p. 249–270.
   Google Scholar